CareRx Résultats passés
Passé contrôle des critères 3/6
CareRx a connu une croissance annuelle moyenne de ses bénéfices de 63.1%, tandis que le secteur Consumer Retailing a vu ses bénéfices augmenter de en baisse à 0.9% par an. Les revenus ont augmenté de en hausse à un taux moyen de 6.6% par an. Le rendement des capitaux propres de CareRx est 24.5% et ses marges nettes sont de 7.1%.
Informations clés
63.13%
Taux de croissance des bénéfices
67.43%
Taux de croissance du BPA
| Consumer Retailing Croissance de l'industrie | 10.26% |
| Taux de croissance des recettes | 6.65% |
| Rendement des fonds propres | 24.52% |
| Marge nette | 7.13% |
| Dernière mise à jour des bénéfices | 30 Jun 2026 |
Mises à jour récentes des performances passées
Recent updates
Earnings Miss: CareRx Corporation Missed EPS By 60% And Analysts Are Revising Their Forecasts
It's been a good week for CareRx Corporation ( TSE:CRRX ) shareholders, because the company has just released its...
CRRX: Slightly Lower Growth Assumptions Will Still Support Long Term Upside
Analysts have adjusted their CareRx price target from CA$4.50 to CA$4.25, citing updated assumptions related to slightly lower revenue growth, a modestly adjusted discount rate, a marginally different profit margin outlook, and a small change in the expected future P/E. What's in the News No recent CareRx news items or key developments were provided in the available sources.
CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential
Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Ventilation des recettes et des dépenses
Comment CareRx gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 26 | 377 | 27 | 101 | 0 |
| 31 Mar 26 | 375 | 27 | 100 | 0 |
| 31 Dec 25 | 370 | 26 | 100 | 0 |
| 30 Sep 25 | 366 | 0 | 100 | 0 |
| 30 Jun 25 | 366 | -2 | 100 | 0 |
| 31 Mar 25 | 367 | -4 | 101 | 0 |
| 31 Dec 24 | 367 | -5 | 101 | 0 |
| 30 Sep 24 | 366 | -6 | 98 | 0 |
| 30 Jun 24 | 367 | -7 | 99 | 0 |
| 31 Mar 24 | 369 | -4 | 98 | 0 |
| 31 Dec 23 | 371 | -5 | 98 | 0 |
| 30 Sep 23 | 374 | -6 | 100 | 0 |
| 30 Jun 23 | 378 | -7 | 100 | 0 |
| 31 Mar 23 | 380 | -34 | 101 | 0 |
| 31 Dec 22 | 382 | -34 | 103 | 0 |
| 30 Sep 22 | 384 | -34 | 101 | 0 |
| 30 Jun 22 | 358 | -36 | 94 | 0 |
| 31 Mar 22 | 311 | -20 | 83 | 0 |
| 31 Dec 21 | 263 | -23 | 71 | 0 |
| 30 Sep 21 | 212 | -21 | 61 | 0 |
| 30 Jun 21 | 187 | -24 | 55 | 0 |
| 31 Mar 21 | 177 | -29 | 52 | 0 |
| 31 Dec 20 | 162 | -18 | 48 | 0 |
| 30 Sep 20 | 148 | -50 | 44 | 0 |
| 30 Jun 20 | 134 | -47 | 42 | 0 |
| 31 Mar 20 | 126 | -34 | 41 | 0 |
| 31 Dec 19 | 125 | -46 | 41 | 0 |
| 30 Sep 19 | 122 | -19 | 42 | 0 |
| 30 Jun 19 | 119 | -20 | 41 | 0 |
| 31 Mar 19 | 117 | -39 | 41 | 0 |
| 31 Dec 18 | 119 | -35 | 41 | 0 |
| 30 Sep 18 | 85 | -27 | 27 | 0 |
| 30 Jun 18 | 97 | -23 | 31 | 0 |
| 31 Mar 18 | 110 | -3 | 34 | 0 |
| 31 Dec 17 | 122 | -4 | 38 | 0 |
| 30 Sep 17 | 168 | -6 | 55 | 0 |
| 30 Jun 17 | 170 | -3 | 56 | 0 |
| 31 Mar 17 | 170 | -13 | 58 | 0 |
| 31 Dec 16 | 167 | -18 | 59 | 0 |
| 30 Sep 16 | 166 | -21 | 64 | 0 |
| 30 Jun 16 | 166 | -34 | 66 | 0 |
| 31 Mar 16 | 164 | -30 | 67 | 0 |
| 31 Dec 15 | 161 | -35 | 67 | 0 |
| 30 Sep 15 | 27 | -47 | 13 | 0 |
Des revenus de qualité: CRRX a un important ponctuel perte de CA$1.3M impactant ses 12 derniers mois de résultats financiers à 30th June, 2026.
Augmentation de la marge bénéficiaire: CRRX est devenu rentable dans le passé.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CRRX est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 63.1% par an.
Accélération de la croissance: CRRX est devenu rentable au cours de l'année dernière, ce qui rend le taux de croissance des bénéfices difficile à comparer à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: CRRX est devenue rentable au cours de l'année dernière, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Consumer Retailing ( 15.5% ).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de CRRX ( 24.5% ) est considéré comme élevé.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/06 02:42 |
| Cours de l'action en fin de journée | 2026/08/06 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CareRx Corporation est couverte par 11 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |